[Three Cases of Encorafenib Treatment for Recurrent BRAF-Mutated Colorectal Cancer].

BACKGROUND

Recently, favorable outcomes from encorafenib treatment have been reported in patients with BRAF-mutated colorectal cancer, which has a poor prognosis.

CASES: Encorafenib was administered to three patients with recurrence after surgery for BRAF-mutated colorectal cancer. Encorafenib and cetuximab were administered to 2 patients, and encorafenib, binimetinib, and cetuximab were administered to one patient. In all cases, tumor markers decreased, and the metastatic tumors shrank. No severe adverse effects were observed.

DISCUSSION: BRAF-mutated colorectal cancer often occurs in the right colon. It is also common in older patients, women, and patients with poorly differentiated tumors; our cases exhibited similar characteristics. As previously reported, both doublet and triplet encorafenib treatments are safe and effective.

CONCLUSION

Combination therapy with encorafenib was effective for the treatment of recurrent BRAF-mutated colorectal cancer, showing good tumor control with few adverse effects. Therefore, this may be a useful treatment option.